VYCO VYCOR MEDICAL INC

OTC Surgical & Medical Instruments & Apparatus DE CIK: 0001424768
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

Despite impressive 17% revenue growth and 84% gross margins indicating sound unit economics, VYCO faces critical financial distress with negative stockholders equity (-4.1M), extreme liquidity crisis (0.12x current ratio), and negative operating cash flow. The company lacks sufficient cash reserves (87K) to service 4.9M in liabilities and sustain ongoing negative burn.

Strengths

  • + Revenue growth of 17.2% YoY demonstrates genuine market demand for products
  • + Exceptional gross margin of 83.8% indicates strong pricing power and operational efficiency in product delivery
  • + Positive operating income of 33.9K shows business model can approach profitability at operational level

Risks

  • ! Negative stockholders equity of -4.1M indicates technical insolvency with liabilities exceeding assets
  • ! Critical liquidity crisis with current ratio of 0.12x and only 87K cash against 4.9M total liabilities
  • ! Negative operating cash flow (-13.5K) and free cash flow (-18.7K) indicate company cannot self-fund and is consuming remaining cash reserves

Key Metrics to Watch

Financial Metrics

Revenue
1.9M
Net Income
-72.4K
EPS (Diluted)
$-0.01
Free Cash Flow
-18.7K
Total Assets
830.4K
Cash
87.0K

Profitability Ratios

Gross Margin 83.8%
Operating Margin 1.8%
Net Margin -3.9%
ROE N/A
ROA -8.7%
FCF Margin -1.0%

Balance Sheet & Liquidity

Current Ratio
0.12x
Quick Ratio
0.08x
Debt/Equity
N/A
Debt/Assets
592.1%
Interest Coverage
2.57x
Long-term Debt
150.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-18T23:27:22.031228 | Data as of: 2025-12-31 | Powered by Claude AI